Skip to main content
TipRanks
Go Ultimate75% OFF

Zenas BioPharma, Inc. (ZBIO) Drug Pipeline

322 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
OrelabrutinibSecondary Progressive Multiple SclerosisPhase IIIRecruitingA Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisDec 18, 2025
OrelabrutinibMultiple Sclerosis (Ms) Primary ProgressivePhase IIIRecruitingA Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisJul 03, 2025
ObexelimabSystemic Lupus ErythematosusPhase IIActive Not RecruitingA Study of Obexelimab in Patients With Systemic Lupus ErythematosusAug 14, 2024―
Zb002Healthy Volunteers, Rheumatoid ArthritisPhase ICompletedA Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid ArthritisNov 15, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Zenas BioPharma, Inc. (ZBIO) have in its pipeline
Zenas BioPharma, Inc. ZBIO is currently developing the following drugs: Orelabrutinib, Obexelimab, Zb002. These drug candidates are in various stages of clinical development as the company works toward FDA approval.